Milnacipran Holsten (Milnacipran Hydrochloride)

Milnacipran, the active ingredient in Milnacipran Holsten, is a serotonin‑norepinephrine reuptake inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. The medication works by increasing the levels of serotonin and norepinephrine in the brain, which helps improve mood and alleviate depressive symptoms.

GNH USA supplies Milnacipran Holsten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milnacipran Holsten belongs to the serotonin‑norepinephrine reuptake inhibitor class and is used in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves functional outcomes in adult patients.

Milnacipran may cause a range of adverse reactions, some of which are more frequent than others.

Common Side Effects: - Nausea - Headache - Constipation - Dry mouth

Serious or Rare Side Effects: - Increased blood pressure - Hepatic dysfunction - Serotonin syndrome (potentially life‑threatening)

Before initiating therapy, clinicians should consider several safety measures.

- Monitor blood pressure: check regularly, especially during dose titration. - Assess for suicidal ideation: observe patients closely during the first weeks of treatment. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Review concomitant serotonergic agents: evaluate risk of serotonin syndrome. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Milnacipran can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs) - Other serotonin‑norepinephrine reuptake inhibitors (SNRIs) - Triptan medications for migraine

Moderate Interactions (Monitor Closely): - Antihypertensive agents (possible additive blood‑pressure effects) - CYP2D6 inhibitors (may increase milnacipran plasma levels) - Non‑steroidal anti‑inflammatory drugs (risk of gastrointestinal bleeding)